
Diabetes
Latest News

Tirzepatide Real-World Benefit Found Greater for CV, Renal Outcomes vs GLP-1 RAs in Adults with T2D
Latest Videos

More News

The panel concludes its discussion with key takeaways on the optimal care of patients with type 1 diabetes care and thoughts on unmet needs within the treatment space.

Focusing on logistical matters as it pertains to teplizumab administration, the panel discusses infusion site considerations, insurance coverage hurdles, and the process of getting patients approved.

Diabetes specialists outline the patient selection protocol for teplizumab and describe the teplizumab infusion process.

Experts on type 1 diabetes discuss the availability of local medical facilities that offer teplizumab screening and evaluation services for individuals at risk of progression of disease.

Amy Burton, MD, reviews findings from the TN-10 study investigating teplizumab, an anti-CD3 monoclonal antibody, for prevention of diabetes in relatives at risk for T1D.

Diabetes experts discuss the important role of teplizumab in delaying the onset of type 1 diabetes and provide insights on the drug’s mechanism of action.

Following audience polls, the panelists provide clinical insights into their screening practices for patients with type 1 diabetes, highlighting key antibodies they screen for.

Audience polls provide the panel insights into common screening practices for patients with type 1 diabetes.

The panel outlines the stages of type 1 diabetes, focusing on the importance of early intervention to prevent complications of the disease.

A panel of experts on type 1 diabetes (T1D) describe the prevalence and burden of the disease, highlighting the emotional and socio-economic burden extending beyond medical expenses.

Your daily dose of the clinical news you may have missed.

Hypoglycemia unawareness increased over time with use of sulfonylureas but decreased with use of insulin over the same period, a new study found.

Adherence to Mediterranean diet-based interventions was associated with reductions in BP, triglycerides, total cholesterol, and LDL-C, as well as increases in HDL-C among children and adolescents.

Results from secondary analysis suggest future work is needed to extend the prevention intervention to address additional chronic conditions and substance use.

Your daily dose of the clinical news you may have missed.

The antigen-specific immunotherapy preserves endogenous insulin production via intralymphatic injection of recombinant GAD65 protein, according to Diamyd Medical.

The oral GLP-1 RA was associated with weight loss of 7.3% in just 4 weeks and is designed with unique properties that will enhance multiple outcomes, Roche said.

The expert panel concludes by analyzing a patient case and offering final insights on customizing treatment for complex geriatric diabetes patients, taking into account cardiovascular health, weight management, and renal function considerations.

Key opinion leaders explore methods for optimizing treatment in older adults with type 2 diabetes, focusing on streamlining regimens and the process of deprescribing, with particular emphasis on defining and implementing the deprescribing approach.

Experts examine strategies for managing treatment modifications in older adults with type 2 diabetes, weighing the approaches, challenges, and advantages of combination therapy regimens.

Leading experts in geriatric diabetes care explore comprehensive aspects of insulin therapy, including dosing strategies, available injectable options, and methods for tailoring glucose control in elderly patients.

The panelists analyze a patient case, examining treatment profiles, adherence factors, and drug class selection criteria while discussing strategies to enhance elderly care.

Key opinion leaders explore strategies for enhancing elderly patient care by implementing American Diabetes Association guidelines on glycemic targets and long-term management in geriatric settings.

Your daily dose of the clinical news you may have missed.

In the mouse model of type 1 diabetes, a combined harmine/exendin-4 therapy resulted in an up to 7-fold increase in β cell numbers over 3 months, reported investigators.


















































































































































































































































































































